Unione Europea - svedese - EMA (European Medicines Agency)

pharmathen s.a. - ibandronsyra - hypercalcemia; fractures, bone; neoplasm metastasis; breast neoplasms - läkemedel för behandling av bensjukdomar - concentrate for solution for infusion prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. behandling av tumör-inducerad hypercalcaemia med eller utan metastaser. film-coated tablets prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.

Unione Europea - svedese - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cystisk fibros - andra andningsorganprodukter - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Unione Europea - svedese - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 och 5. 1 för tillgänglig data på olika kombinationer).

Unione Europea - svedese - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - immunsuppressiva - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.

Unione Europea - svedese - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - nintedanib - idiopatisk lungfibros - antineoplastiska medel - ofev är indicerat hos vuxna för behandling av idiopatisk lungfibros (ipf).

Unione Europea - svedese - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin, metformin hydroklorid - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - vokanamet är indicerat hos vuxna i åldern 18 år och äldre med typ 2-diabetes som ett komplement till diet och motion för att förbättra glykemisk kontroll:i patienter som inte kontrolleras på ett adekvat sätt om deras maximalt tolererad dos av metformin alonein patienter om deras maximalt tolererad dos av metformin tillsammans med andra glukos sänka läkemedel, inklusive insulin, när dessa inte ger tillräcklig glykemisk kontroll. hos patienter som redan behandlas med en kombination av canagliflozin och metformin som separata tabletsfor studie resultat med hänsyn till en kombination av behandlingar, effekter på glykemisk kontroll och kardiovaskulära händelser, och de populationer som studeras, se avsnitt 4. 4, 4. 5 och 5.

Unione Europea - svedese - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - bröst-neoplasmer - antineoplastiska medel - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Svezia - svedese - Läkemedelsverket (Medical Products Agency)

teva sweden ab - fluorouracil - injektionsvätska, lösning - 50 mg/ml - fluorouracil 50 mg aktiv substans - fluorouracil

Svezia - svedese - Läkemedelsverket (Medical Products Agency)

accord healthcare b.v. - fluorouracil - injektions-/infusionsvätska, lösning - 50 mg/ml - fluorouracil 50 mg aktiv substans - fluorouracil

Svezia - svedese - Läkemedelsverket (Medical Products Agency)

b. braun melsungen ag - metronidazol - infusionsvätska, lösning - 5 mg/ml - metronidazol 5 mg aktiv substans - metronidazol